d Changes in blood pressure in the group of increase in potency. SBP significantly decreased from 161.7 ± 18.2 to 143.6 ± 25.3 mmHg (p < 0.001) and DBP significantly decreased from 89.4 ± 11.2 to 82.3 ± 15.0 mmHg (p = 0.018) We then examined the factors which correlated with the change in blood pressures. The changes of potency were significantly associated with the changes of SBP and DBP (Spearman’s ρ = −0.305, p = 0.003

and ρ = −0.247, p = 0.019). The decrease of the drug costs was also associated with the lowering of SBP and DBP (Pearson r = −0.291, p = 0.005 and r = −0.216, p = 0.041). Criteria for switching treatments to combined drugs To examine how attending physicians switched the treatments, we compared the recipe before and after Carfilzomib cost the switch. In most cases, combination drugs were chosen based on the ARB and CCB previously used. Patients who had already been using the same agents of ARB and CCB as those present in the combined drugs accounted GSK3235025 datasheet for 36.7 % (n = 33). In this group, neither SBP (from 136.5 ± 20.1 to 135.1 ± 19.5 mmHg, p = 0.60) nor DBP (from 83.1 ± 13.9 to 80.2 ± 12.7 mmHg, p = 0.17)

significantly changed. The potency did not change from 2.38 ± 0.80 to 2.31 ± 0.77 (p = 0.19) but the number of antihypertensive tablet dramatically decreased from 2.49 ± 0.78 to 1.33 ± 0.53 (p < 0.001) as well as the number of total tablets (from 5.51 ± 5.11 to 4.36 ± 4.80, p < 0.001), Liothyronine Sodium and costs of antihypertensive drugs appreciably decreased from 7,089 ± 2,114 to 5,697 ± 2,949 yen (p < 0.001). The second highest cases were the patients whose treatment had been switched or added on the basis of the ARB, and accounted for 28.9 % (n = 26). In this group, SBP decreased from 141.8 ± 19.0 to 133.4 ± 19.0 mmHg (p = 0.01) but DBP did not (from 79.7 ± 12.2 to 76.4 ± 11.1 mmHg, p = 0.15). The potency did not change from 2.73 ± 1.45 to 2.46 ± 0.88 (p = 0.20) but the number of antihypertensive tablet significantly decreased from 3.31 ± 1.79 to 2.08 ± 1.35 (p < 0.001) as well as the

number of total tablets changed (from 10.1 ± 7.85 to 9.20 ± 8.28, p = 0.005), and costs of antihypertensive drugs also decreased from 8,569 ± 3,344 to 5,740 ± 1,869 yen (p < 0.001). The third highest cases were the patients whose treatment had been switched or added on the basis of the CCB; they accounted for 14.4 % of the cases (n = 13). In this group, SBP decreased from 152.0 ± 17.3 to 133.2 ± 17.9 mmHg (p = 0.02) as well as DBP (from 84.7 ± 14.0 to 75.7 ± 14.2 mmHg, p = 0.007). However, the potency did not change from 2.18 ± 0.97 to 2.19 ± 0.61 (p = 0.96). The number of antihypertensive tablet decreased from 2.46 ± 0.93 to 1.15 ± 0.36 (p < 0.001) but neither the number of total tablets (from 6.69 ± 3.93 to 5.77 ± 4.58, p = 0.